Evidence method
Level · gp.fundamentals.cash
$131.1M · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CRVL · Sep 30, 2021
CORVEL CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-21-003100Insurance
Evidence method
Yoy · gp.fundamentals.net_income
35.46% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
15.96% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History28 statesSelf-history eligible
Sep 30, 20213/3 normalizedLevel 3Dec 31, 20213/3 normalizedLevel 3Mar 31, 20223/3 normalizedLevel 3Jun 30, 20223/3 normalizedLevel 3Sep 30, 20223/3 normalizedLevel 3Dec 31, 20223/3 normalizedLevel 3Mar 31, 20233/3 normalizedLevel 3Jun 30, 20233/3 normalizedLevel 3Sep 30, 20233/3 normalizedLevel 3Dec 31, 20233/3 normalizedLevel 3Mar 31, 20243/3 normalizedLevel 3Jun 30, 20243/3 normalizedLevel 3Sep 30, 20243/3 normalizedLevel 3Dec 31, 20243/3 normalizedLevel 3Mar 31, 20253/3 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20263/3 normalizedLevel 3Jun 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- $138.7M
- Current
- $131.1M
- Delta
- -$7.6M
- Previous
- 102.88%
- Current
- 35.46%
- Delta
- -67.42%
- Previous
- 17.76%
- Current
- 15.96%
- Delta
- -1.80%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.